19
Owens, D. E., III, & Peppas, N. A. (2006). Opsonization, biodistribution, and pharmacokinetics of
polymeric nanoparticles. International Journal of Pharmaceutics, 307(1), 93–102. https://doi.
org/10.1016/j.ijpharm.2005.10.010.
Pandey, M. K., Balwani, S., Sharma, P. K., Parmar, V. S., Ghosh, B., & Watterson,
A. C. (2010). Design, synthesis and anti-inflammatory evaluation of PEGylated 4-methyl and
4,8- dimethylcoumarins. European Journal of Pharmaceutical Sciences, 39(1–3), 134–140.
https://doi.org/10.1016/j.ejps.2009.11.008.
Pelegri-O’Day, E. M., Lin, E. W., & Maynard, H. D. (2014). Therapeutic protein-polymer conjugates: Advancing beyond PEGylation. Journal of the American Chemical Society, 136(41),
14323–14332. https://doi.org/10.1021/ja504390x.
Peng, Y. M., Nie, J. P., Cheng, W., Liu, G., Zhu, D. W., Zhang, L. H., Liang, C. Y., Mei, L.,
Huang, L. Q., & Zeng, X. W. (2018). A multifunctional nanoplatform for cancer chemophotothermal synergistic therapy and overcoming multidrug resistance. Biomaterials Science,
6(5), 1084–1098. https://doi.org/10.1039/c7bm01206c.
Rapoport, N. (2007). Physical stimuli-responsive polymeric micelles for anti-cancer drug
delivery. Progress in Polymer Science, 32(8–9), 962–990. https://doi.org/10.1016/j.
progpolymsci.2007.05.009.
Reichert, C., & Borchard, G. (2016). Noncovalent PEGylation, an innovative subchapter in the
field of protein modification. Journal of Pharmaceutical Sciences, 105(2), 386–390. https://
doi.org/10.1002/jps.24692.
Roque, L., Castro, P., Molpeceres, J., Viana, A. S., Roberto, A., Reis, C., Rijo, P., Tho, I., Sarmento,
B., & Reis, C. (2018). Bioadhesive polymeric nanoparticles as strategy to improve the treatment of yeast infections in oral cavity: in-vitro and ex-vivo studies. European Polymer Journal,
104, 19–31. https://doi.org/10.1016/j.eurpolymj.2018.04.032.
Sabino, M. A., Albuerne, J., Müller, A. J., Brisson, J., & Prud’homme, R. E. (2004). Influence
of in vitro hydrolytic degradation on the morphology and crystallization behavior of poly(pdioxanone). Biomacromolecules, 5(2), 358–370. https://doi.org/10.1021/bm034367i.
Sánchez-López, E., Ettcheto, M., Egea, M. A., Espina, M., Cano, A., Calpena, A. C., Camins,
A., Carmona, N., Silva, A. M., & Souto, E. B. (2018). Memantine loaded PLGA PEGylated
nanoparticles for Alzheimer’s disease: In vitro and in vivo characterization. Journal of
Nanobiotechnology, 16(1), 32. https://doi.org/10.1186/s12951-018-0356-z.
Sharma, S., Parmar, A., Kori, S., & Sandhir, R. (2016). PLGA-based nanoparticles: A new paradigm in biomedical applications. TrAC Trends in Analytical Chemistry, 80, 30–40. https://doi.
org/10.1016/j.trac.2015.06.014.
Shi, Y. A., Sun, X. F., Zhang, L. P., Sun, K. X., Li, K. K., Li, Y. X., & Zhang, Q. (2018).
Fc-modified exenatide-loaded nanoparticles for oral delivery to improve hypoglycemic effects
in mice. Scientific Reports, 8, 726. https://doi.org/10.1038/s41598-018-19170-y.
Shih, C. (1995). Chain-end scission in acid catalyzed hydrolysis of poly(D,L-lactide) in solution.
Journal of Controlled Release, 34(1), 9–15. https://doi.org/10.1016/0168-3659(94)00100-9.
Silva-Abreu, M., Espinoza, L., Halbaut, L., Espina, M., García, M., & Calpena, A. (2018).
Comparative study of ex vivo transmucosal permeation of pioglitazone nanoparticles for the treatment of Alzheimer’s disease. Polymers, 10(3), 316. https://doi.org/10.3390/polym10030316.
Soppimath, K. S., Aminabhavi, T. M., Kulkarni, A. R., & Rudzinski, W. E. (2001). Biodegradable
polymeric nanoparticles as drug delivery devices. Journal of Controlled Release, 70(1–2),
1–20. https://doi.org/10.1016/s0168-3659(00)00339-4.
Stidl, R., Denne, M., Goldstine, J., Kadish, B., Korakas, K. I., & Turecek, P. L. (2018). Polyethylene
glycol exposure with antihemophilic factor (recombinant), PEGylated (rurioctocog alfa pegol)
and other therapies indicated for the pediatric population: History and safety. Pharmaceuticals
(Basel), 11(3), 75. https://doi.org/10.3390/ph11030075.
Swierczewska, M., Lee, K. C., & Lee, S. (2015). What is the future of PEGylated therapies?
Expert Opinion on Emerging Drugs, 20(4), 531–536. https://doi.org/10.1517/14728214.201
5.1113254.
2 Biodegradable and Functional Synthetic Polymers in Nanomedicine: Controlled…
Owens, D. E., III, & Peppas, N. A. (2006). Opsonization, biodistribution, and pharmacokinetics of
polymeric nanoparticles. International Journal of Pharmaceutics, 307(1), 93–102. https://doi.
org/10.1016/j.ijpharm.2005.10.010.
Pandey, M. K., Balwani, S., Sharma, P. K., Parmar, V. S., Ghosh, B., & Watterson,
A. C. (2010). Design, synthesis and anti-inflammatory evaluation of PEGylated 4-methyl and
4,8- dimethylcoumarins. European Journal of Pharmaceutical Sciences, 39(1–3), 134–140.
https://doi.org/10.1016/j.ejps.2009.11.008.
Pelegri-O’Day, E. M., Lin, E. W., & Maynard, H. D. (2014). Therapeutic protein-polymer conjugates: Advancing beyond PEGylation. Journal of the American Chemical Society, 136(41),
14323–14332. https://doi.org/10.1021/ja504390x.
Peng, Y. M., Nie, J. P., Cheng, W., Liu, G., Zhu, D. W., Zhang, L. H., Liang, C. Y., Mei, L.,
Huang, L. Q., & Zeng, X. W. (2018). A multifunctional nanoplatform for cancer chemophotothermal synergistic therapy and overcoming multidrug resistance. Biomaterials Science,
6(5), 1084–1098. https://doi.org/10.1039/c7bm01206c.
Rapoport, N. (2007). Physical stimuli-responsive polymeric micelles for anti-cancer drug
delivery. Progress in Polymer Science, 32(8–9), 962–990. https://doi.org/10.1016/j.
progpolymsci.2007.05.009.
Reichert, C., & Borchard, G. (2016). Noncovalent PEGylation, an innovative subchapter in the
field of protein modification. Journal of Pharmaceutical Sciences, 105(2), 386–390. https://
doi.org/10.1002/jps.24692.
Roque, L., Castro, P., Molpeceres, J., Viana, A. S., Roberto, A., Reis, C., Rijo, P., Tho, I., Sarmento,
B., & Reis, C. (2018). Bioadhesive polymeric nanoparticles as strategy to improve the treatment of yeast infections in oral cavity: in-vitro and ex-vivo studies. European Polymer Journal,
104, 19–31. https://doi.org/10.1016/j.eurpolymj.2018.04.032.
Sabino, M. A., Albuerne, J., Müller, A. J., Brisson, J., & Prud’homme, R. E. (2004). Influence
of in vitro hydrolytic degradation on the morphology and crystallization behavior of poly(pdioxanone). Biomacromolecules, 5(2), 358–370. https://doi.org/10.1021/bm034367i.
Sánchez-López, E., Ettcheto, M., Egea, M. A., Espina, M., Cano, A., Calpena, A. C., Camins,
A., Carmona, N., Silva, A. M., & Souto, E. B. (2018). Memantine loaded PLGA PEGylated
nanoparticles for Alzheimer’s disease: In vitro and in vivo characterization. Journal of
Nanobiotechnology, 16(1), 32. https://doi.org/10.1186/s12951-018-0356-z.
Sharma, S., Parmar, A., Kori, S., & Sandhir, R. (2016). PLGA-based nanoparticles: A new paradigm in biomedical applications. TrAC Trends in Analytical Chemistry, 80, 30–40. https://doi.
org/10.1016/j.trac.2015.06.014.
Shi, Y. A., Sun, X. F., Zhang, L. P., Sun, K. X., Li, K. K., Li, Y. X., & Zhang, Q. (2018).
Fc-modified exenatide-loaded nanoparticles for oral delivery to improve hypoglycemic effects
in mice. Scientific Reports, 8, 726. https://doi.org/10.1038/s41598-018-19170-y.
Shih, C. (1995). Chain-end scission in acid catalyzed hydrolysis of poly(D,L-lactide) in solution.
Journal of Controlled Release, 34(1), 9–15. https://doi.org/10.1016/0168-3659(94)00100-9.
Silva-Abreu, M., Espinoza, L., Halbaut, L., Espina, M., García, M., & Calpena, A. (2018).
Comparative study of ex vivo transmucosal permeation of pioglitazone nanoparticles for the treatment of Alzheimer’s disease. Polymers, 10(3), 316. https://doi.org/10.3390/polym10030316.
Soppimath, K. S., Aminabhavi, T. M., Kulkarni, A. R., & Rudzinski, W. E. (2001). Biodegradable
polymeric nanoparticles as drug delivery devices. Journal of Controlled Release, 70(1–2),
1–20. https://doi.org/10.1016/s0168-3659(00)00339-4.
Stidl, R., Denne, M., Goldstine, J., Kadish, B., Korakas, K. I., & Turecek, P. L. (2018). Polyethylene
glycol exposure with antihemophilic factor (recombinant), PEGylated (rurioctocog alfa pegol)
and other therapies indicated for the pediatric population: History and safety. Pharmaceuticals
(Basel), 11(3), 75. https://doi.org/10.3390/ph11030075.
Swierczewska, M., Lee, K. C., & Lee, S. (2015). What is the future of PEGylated therapies?
Expert Opinion on Emerging Drugs, 20(4), 531–536. https://doi.org/10.1517/14728214.201
5.1113254.
2 Biodegradable and Functional Synthetic Polymers in Nanomedicine: Controlled…